Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients in Magnetic Resonance Imaging

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients will be recruited from those who will undergo contrast enhanced MRI. Safety and tolerability will be assessed.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer

Criteria

Inclusion Criteria:

• 18 years old and above undergoing contrast enhanced cranial or spinal MRI with Gadobutrol (Gadovist)

Exclusion Criteria:

• History of hypersensitivity reaction to gadolinium containing contrast material

• Hypersensitivity to any of the ingredients of Gadobutrol (Gadovist)

• History of hypersensitivity to any other contrast agent

• Patients with uncorrected hypokalemia

• Pregnant and lactating women

• Patients with severe cardiovascular diseases

• Patients in whom MRI cannot be performed.